论文部分内容阅读
三阴性乳腺癌（ TNBC）是指雌激素受体（ ER）、孕激素受体（ PR）及人类上皮细胞生长因子受体2（HER2）均无表达的一类乳腺癌，与其他乳腺癌相比，TNBC对新辅助化疗的完全病理缓解率较高，效果较好，然而，仍有超过半数的 TNBC 不能达到完全病理缓解，预后较差，目前，很多学者致力于研究细胞毒药物、靶向药物等对TNBC的治疗。针对不同亚型的TNBC，新辅助化疗的组合方式及有效的药物靶点、可靠的预后标志等将会是本领域研究的热点。“,”Triple-negative breast cancer( TNBC) is defined by the lack of immunohistochemical expres-sion of the estrogen receptors(ER),progesterone receptors(PR) and human epidermal growth factor receptor 2 (HER2).Historically,TNBC has responded well in the neoadjuvant setting,with rates of pathological com-plete response commonly higher than for other breast tumor types.However,more than half of TNBC patients do not achieve a pathological complete response and have a poor prognosis.Many studies have addressed improving the efficacy of neoadjuvant chemotherapy by including different cytotoxic agents and targeted agents.For different subtypes of TNBC,combination of neoadjuvant chemotherapy,effective target and prog-nostic indicator will be the hot spot in the clinical study.